 |
 |
|
|
|
| Rifaximin |
 |
| orange red powder |
 |
| 80621-81-4 |
 |
Rifaximin is licensed by the U.S. Food and Drug Administration to treat traveler's diarrhea caused by E. coli.Clinical trials have shown that rifaximin is highly effective at preventing and treating traveler's diarrhea among travelers to Mexico, with few side effects and low risk of developing antibiotic resistance.It is not effective against Campylobacter jejuni, and there is no evidence of efficacy against Shigella or Salmonella species.
|
 |
Product name:Rifaximin
Synonyms:3-Hydroxy-2-methyl-4-pyrone
3-Hydroxy-2-methyl-4H-pyran-4-one
CAS:80621-81-4
MF:C43H51N3O11
MW:785.88
Appearence:orange red powder
Assay:99%
Uses:
Rifaximin is licensed by the U.S. Food and Drug Administration to treat traveler's diarrhea caused by E. coli.Clinical trials have shown that rifaximin is highly effective at preventing and treating traveler's diarrhea among travelers to Mexico, with few side effects and low risk of developing antibiotic resistance.It is not effective against Campylobacter jejuni, and there is no evidence of efficacy against Shigella or Salmonella species.
It may be efficacious in relieving chronic functional symptoms of bloating and flatulence that are common in irritable bowel syndrome (IBS).
There was recently a pilot-study done on the efficacy of rifaximin as a means of treatment for rosacea, according to the study, induced by the co-presence of small intestinal bacterial overgrowth.
In the United States, rifaximin has orphan drug status for the treatment of hepatic encephalopathy.Although high-quality evidence is still lacking, rifaximin appears to be as effective as or more effective than other available treatments for hepatic encephalopathy (such as lactulose), is better tolerated, and may work faster.The drawbacks to rifaximin are increased cost and lack of robust clinical trials for HE without combination lactulose therapy. |
|
|
|
|
|
